Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 251

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 251
---
.2, 4.3, and 4.4 to the Form 6-K dated August 16, 2024, and are incorporated herein by reference.

Initial Closing

On August 12, 2024, the Company
and the Buyers consummated the Initial Closing. The Initial Note sold in connection with the Securities Purchase Agreement bears an interest
rate of 14.75% per annum and is convertible into the Company’s Class A Ordinary Shares as follows: the Conversion Amount (as defined
in the Initial Note) into validly issued, fully paid and non-assessable Class A Ordinary Shares at the Conversion Rate (as defined in
the Initial Note); subject to adjustment as provided therein. No fractional Class A Ordinary Shares are issuable upon any such conversion.
A holder may convert the Initial Notes at any time after the initial issuance date of such Initial Note, subject to the Maximum Percentage.

The form of the Initial Note
is included as Exhibit A of the Securities Purchase Agreement filed as Exhibit 4.1 in the Form 6-K dated August 15, 2024.

At the Initial Closing, the
Company also sold to the Buyers Series A Warrants to purchase an aggregate 1,325,301 Class A Ordinary Shares (without reflecting any Reverse
Stock Splits) and Series B Warrants to purchase an aggregate 180,722 Class A Ordinary Shares (without reflecting any Reverse Stock Splits).

Series A Warrants.

The
Series A Warrants expire nine years after the issuance date and are initially exercisable for an aggregate of 1,325,301 Class A Ordinary
Shares (the “Series A Warrant Shares”), subject to adjustment as provided therein. The initial exercise price of the Series
A Warrants is $0.913 per share, subject to adjustment as provided therein. If at the time of exercise of the Series A Warrants, there
is no effective registration statement registering the shares of our Ordinary Shares underlying such warrants, such warrants may be exercised
on a cashless basis pursuant to their terms.

Series B Warrants

The Series B Warrants expire
nine years after the issuance date and are initially exercisable for an aggregate of 180,722 Ordinary Shares, subject to adjustment as
provided therein. The Series B Warrants may be exercised at any time on or after February 12, 2025 (the “Initial Exercise Eligibility
Date”), subject to the Maximum Percentage. The initial exercise price of the Series B Warrants was prepaid, except